Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Nucleotide Excision Repair01:38

Nucleotide Excision Repair

4.9K
DNA Distortion and Damage
Cells are regularly exposed to mutagens—factors in the environment that can damage DNA and generate mutations. UV radiation is one of the most common mutagens and is estimated to introduce a significant number of changes in DNA. These include bends or kinks in the structure, which can block DNA replication or transcription. If these errors are not fixed, the damage can cause mutations, which in turn can result in cancer or disease depending on which sequences are...
4.9K
Abnormal Proliferation02:23

Abnormal Proliferation

5.0K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.0K
DNA Damage can Stall the Cell Cycle02:36

DNA Damage can Stall the Cell Cycle

9.9K
In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...
9.9K
DNA Damage Can Stall the Cell Cycle02:36

DNA Damage Can Stall the Cell Cycle

3.0K
In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...
3.0K
Long-patch Base Excision Repair01:02

Long-patch Base Excision Repair

7.8K
Since the discovery of the two BER pathways, there has been a debate about how a cell chooses one pathway over the other and the factors determining this selection. Numerous in vitro experiments have pointed out multiple determinants for the sub-pathway selection. These are:
7.8K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Genomic analysis of oesophageal carcinoma (EC) identifies recurrent mutations in histone methyltransferases as a distinctive subset.

Oncogene·2026
Same author

Activation of the endocytosis pathway stratifies subtypes and therapeutic sensitivity in colorectal cancer.

Research square·2026
Same author

Molecular-level traits of root exudates in tropical forest trees reflect nitrogen-fixation strategy and phenological shifts.

The New phytologist·2026
Same author

Risk of Hypoglycemia and Associated Factors Among In-Hospital Chinese Patients With Latent Autoimmune Diabetes in Adults (LADA): A Multicenter Retrospective Cohort Study.

Journal of diabetes research·2026
Same author

The IGF1-PGM5 Axis Inhibits Aerobic Glycolysis and Serves As a Tumor Suppressor in Nasopharyngeal Carcinoma.

Journal of biochemical and molecular toxicology·2026
Same author

Supratopological Ion-Coordinated Binder Networks for Durable and Kinetically Efficient Silicon Anodes.

Small (Weinheim an der Bergstrasse, Germany)·2026

Related Experiment Video

Updated: Jan 6, 2026

A Multiplexed Luciferase-based Screening Platform for Interrogating Cancer-associated Signal Transduction in Cultured Cells
10:13

A Multiplexed Luciferase-based Screening Platform for Interrogating Cancer-associated Signal Transduction in Cultured Cells

Published on: July 3, 2013

11.5K

Targeting WEE1 in ARID1A/TP53 Concurrent Mutant Colorectal Cancer by Exploiting R-Loop Accumulation and DNA Repair

Chi Zhang1,2, Yanjing Zhu1,2, Luoyan Ai1,2

  • 1Department of Medical Oncology, Zhongshan Hospital, Fudan University, Shanghai, 200032, China.

Advanced Science (Weinheim, Baden-Wurttemberg, Germany)
|November 30, 2025
PubMed
Summary
This summary is machine-generated.

Colorectal cancers (CRC) with ARID1A and TP53 mutations show sensitivity to WEE1 inhibitors. This targeted therapy, potentially combined with AKT blockade, offers a promising treatment strategy for these specific CRC subtypes.

Keywords:
DNA damage repairR‐loopWEE1 inhibitorscolorectal cancer

More Related Videos

Deficient Pms2, ERCC1, Ku86, CcOI in Field Defects During Progression to Colon Cancer
28:15

Deficient Pms2, ERCC1, Ku86, CcOI in Field Defects During Progression to Colon Cancer

Published on: July 28, 2010

12.7K
Visualization of DNA Repair Proteins Interaction by Immunofluorescence
07:55

Visualization of DNA Repair Proteins Interaction by Immunofluorescence

Published on: June 26, 2020

10.9K

Related Experiment Videos

Last Updated: Jan 6, 2026

A Multiplexed Luciferase-based Screening Platform for Interrogating Cancer-associated Signal Transduction in Cultured Cells
10:13

A Multiplexed Luciferase-based Screening Platform for Interrogating Cancer-associated Signal Transduction in Cultured Cells

Published on: July 3, 2013

11.5K
Deficient Pms2, ERCC1, Ku86, CcOI in Field Defects During Progression to Colon Cancer
28:15

Deficient Pms2, ERCC1, Ku86, CcOI in Field Defects During Progression to Colon Cancer

Published on: July 28, 2010

12.7K
Visualization of DNA Repair Proteins Interaction by Immunofluorescence
07:55

Visualization of DNA Repair Proteins Interaction by Immunofluorescence

Published on: June 26, 2020

10.9K

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Genetics

Background:

  • ARID1A mutations are common in colorectal cancer (CRC).
  • ARID1A is a component of the SWI/SNF tumor suppressor complex.
  • Concurrent mutations in ARID1A and TP53 define a subset of CRC.

Purpose of the Study:

  • To investigate the therapeutic potential of WEE1 inhibitors in ARID1A/TP53 mutant CRC.
  • To elucidate the mechanisms underlying sensitivity to WEE1 inhibition.
  • To explore combination therapies for enhanced antitumor effects.

Main Methods:

  • Chromatin accessibility sequencing to assess transcriptional changes.
  • CRISPR knockout screening to identify synergistic drug targets.
  • Preclinical models and clinical trial data (NCT06363552) analysis.

Main Results:

  • ARID1A deficiency leads to R-loop accumulation and replication stress.
  • Loss of ARID1A impairs ATF3 transcription, exacerbating DNA damage from WEE1 inhibition.
  • A patient with ARID1A/TP53 mutant metastatic CRC showed tumor regression with WEE1 inhibitor therapy.
  • Concurrent AKT blockade significantly enhanced WEE1 inhibitor efficacy in preclinical models.

Conclusions:

  • WEE1 inhibition is a promising therapeutic strategy for ARID1A/TP53 concurrent mutant CRC.
  • Understanding the role of ARID1A in DNA damage response is crucial for targeted therapy.
  • Combination therapy with AKT inhibitors may improve treatment outcomes.